首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma (vol 137, pg 600, 2021)

【24h】

A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma (vol 137, pg 600, 2021)

机译：venetoclax plus r-chec作为弥漫性大B细胞淋巴瘤患者的一线治疗（Vol 137，PG 600,2021）的一阶段2研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2021年第13期|共1页
作者
Morschhauser F.; Feugier P.; Flinn I. W.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis [J] . Yuan-Rong Ren, Yong-Dong Jin, Zhi-Hui Zhang, 中华医学杂志（英文版） . 2015,第003期
2. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma [J] . Xiao-Hui He, Mei Dong, Sheng-Yu Zhou, 癌症（英文版） . 2012,第006期
3. Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2 [J] . Shu Liu, Xia Zhu, Quan-guang Ren, 中国药理学报：英文版 . 2021,第004期
4. Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options [J] . Shuna Yao, Jie Ma, Yan Zhao, 中国癌症研究（英文版） . 2017,第001期
5. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma [J] . Morschhauser Franck, Feugier Pierre, Flinn Ian W., Blood: The Journal of the American Society of Hematology . 2021,第5期

机译：venetoclax plus r-chec作为弥漫性大B细胞淋巴瘤患者的一线治疗的2相研究
6. Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study [J] . Morschhauser Franck, Feugier Pierre, Flinn Ian W., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：威酸葡萄糖加里妥昔单抗，环磷酰胺，多柔比星，血管氨酸和泼尼松酮（R-Chec）改善了Bcl2阳性一线弥漫性大B细胞淋巴瘤（DLBCL）的结果：第一次安全，疗效和生物标志物分析来自II期Cavalli研究
7. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma [J] . Nowakowski Grzegorz S., Chiappella Annalisa, Gascoyne Randy D., Journal of Clinical Oncology . 2021,第12期

机译：鲁棒：在先前未经处理的ABC型弥漫性大B细胞淋巴瘤中，Lenalidomide Plus R-Check对Lenalalomide Plus R-Check的III研究
8. Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models [C] . Chin-Chuan Chang, Chien-Hua Chen, Jer-Guang Hsieh, IEEE Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability . 2021

机译：逻辑和神经网络模型弥漫性大B细胞淋巴瘤患者的存活预测
9. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
10. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma [O] . Mu-Chen Zhang, Ying Fang, Li Wang, 2020

机译：在老年诊断弥漫性大型B细胞淋巴瘤的老年患者中Tucidinostat加入R-Chec患者的临床疗效和分子生物标志物。
11. Bendamustine Plus Rituximab Versus R-Minichop as First-Line Treatment in Unfit Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study in China [O] . Dongdong Zhang, Tao Liu, Natasha Mupeta Kaweme, 2021

机译：Bendamustine Plus Rituximab与R-MINOPOP作为脱裂性大型B细胞淋巴瘤的一线治疗：中国的回顾性研究
12. Pilot Study: Evaluation of the Effects of Treatment with 0.75% Topical Capsaicin in Patients with Reflex Sympathetic Dystrophy Using Three Phase Bone Scintigraphy. [R] . Sinoff, S. E., Hart, M. B. 1991

机译：试验研究：使用三相骨显像评估0.75％局部辣椒素治疗反射性交感神经营养不良患者的效果。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号